Facebook Pixel Code
Haematology/Oncology
Haematology/Oncology

Current Clinical Trials

*For eligibility criteria please click on the trial code. For additional information about current clinical trials and eligibility criteria, please contact our 
Clinical Trials Project Manager, Gina J. Lee at nait.info@sickkids.ca

A PDF version of this information can be found in the form of our monthly NAIT Newsletter.

Trial Code

Summary

Trial
Status

Brain Tumours

Histio-
cytosis

Leukemia/
Lymphoma

Solid Tumours/
Neuro-
blastoma

 

BRF116013

Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study  to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Subjects Aged 1 Month to <18 Years with Advanced BRAF V600-Mutation Positive Solid Tumours.

 

 

Open

TOPAZ

 

A Phase I and Enrichment Study of Low-Dose Metronomic Topotecan and Pazopanib in Pediatric Patients with Recurrent or Refractory Solid Tumours Including CNS Tumours

 

Temporarily closed to accrual

   

 

CLDK378X2103

A Phase I open label dose escalation study of LDK378 in pediatric patients with malignancies that have genetic alteration in anaplastic lymphoma kinase (ALK)

 

Open

 

MEK116540

 

An Open-Label, Dose-Escalation, Phase I/II Study to Investigate
the Safety, Pharma-
cokinetics, Pharma-
codynamics and Clinical
Activity of the MEK Inhibitor Trametinib in Children and
Adolescents Subjects with Cancer or Plexiform Neurofibromas
and Trametinib in Combination with Dabrafenib in Children and
Adolescents with Cancers Harboring V600 mutations

 

Open

 
N2004-05

Neuroblastoma Biology Studies New Approaches to Neuroblastoma Therapy (NANT) biology studies.

 

Open

     

 

N2011-04

A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18                      +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma 

 

Temporarily closed to accrual

     

N2012-01

Phase 1 study of difluoro-
methylornithine (DFMO) and celecoxib with cyclophosph-
amide/topotecan for patients with relapsed or refractory neuroblastoma

 

Open

     

 

N2011-01

Randomized Phase II Study of 131I-MIBG vs. 131I-MIBG with Vincristine and Irinotecan vs. 131I-MIBG with Vorinostat for Resistant/ Relapsed Neuroblastoma



Open

     

 


CFZ008

Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and vincrinstine in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia




Temporarily closed to accrual

   

 

 

 

 

Mel-P1

Phase 1 Dose Finding Study For Melatonin in Pediatric Oncology Patients with Relapsed Solid Tumors

Open

     

ADVL1412

A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Open

   

Afatinib Pediatric Trial 1200-120

Phase I open label, dose escalation, monotherapy trial of afatinib to determine the MTD, safety, PK and efficacy of afatinib in children aged 6 months to <18 years with recurrent/refractory neuroectodermal tumours and rhabdomyosarcoma evaluating ErbB pathway deregulation

Open

   

IND.218

A Study of Vinblastine and Temsirolimus in Pediatric Patients with Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

Temporarily close to accrual

 

EZH102

A Phase 1 Study pf the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Pefractory INI1-Negative Tumors or Synovial Sarcoma

Open

   

T2014-001

A Phase I Trial of Temsirolimus in combination with etoposide and cyclophosphamide in children with relapsed acute ALL with non-Hodgkins lymphoma

Not yet open

     

N2014-01

Phase I study of SF1126 for patients with relapsed or refratory neuroblastoma

Not yet open

     

KTE-C19

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Not yet open

   

 

 

 

 

 

N2015-02

Phase 1/2 study of PF-06463922, an oral small molecule inhibitor of ALK/ROS1, for patients with ALK-driven relapsed or refractory neuroblastoma

Not yet open

     

 

 

 

Find a Paediatric Clinical Trial

  • For other clinical trials conducted in North America and around the world visit clinicaltrials.gov